B7-33 is a single-chain peptide analog of human relaxin-2 engineered to retain relaxin anti-fibrotic activity in a simpler, more synthesizable molecule. It is a preclinical research reagent studied in models of cardiac, lung, and kidney fibrosis, with no human trials and no approved use.
Mechanism under study
A single-chain analog of relaxin-2 that acts as a biased agonist at the RXFP1 receptor, favoring pERK signaling associated with reduced collagen deposition and anti-fibrotic effects in organ-injury models.
Research-reported dosing
No approved or established human dosing; it has been studied only in animal fibrosis and injury models by injection. Reported context only.
Research lyophilate. A 5 mg vial reconstituted with 2 mL bacteriostatic water yields 2,500 mcg/mL (2.5 mg/mL); on a U-100 syringe 1 unit (0.01 mL) is about 25 mcg. Research use only.
Open this mix in the calculator →Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
B7-33 FAQ
What is B7-33?
B7-33 is a single-chain peptide analog of human relaxin-2 engineered to retain relaxin anti-fibrotic activity in a simpler, more synthesizable molecule. It is a preclinical research reagent studied in models of cardiac, lung, and kidney fibrosis, with no human trials and no approved use.
What is the half-life of B7-33?
Short; reported on the order of minutes in preclinical work.
What is the research-reported dosing for B7-33?
No approved or established human dosing; it has been studied only in animal fibrosis and injury models by injection. Reported context only.
How is B7-33 reconstituted?
Research lyophilate. A 5 mg vial reconstituted with 2 mL bacteriostatic water yields 2,500 mcg/mL (2.5 mg/mL); on a U-100 syringe 1 unit (0.01 mL) is about 25 mcg. Research use only.
Is B7-33 FDA-approved?
No — B7-33 is not FDA-approved and is sold for laboratory research use only.
References
Related peptides
Serelaxin (Recombinant Relaxin-2)
Recombinant peptide hormone (relaxin-2)
Serelaxin is recombinant human relaxin-2 (RLX030) studied mainly as a short intravenous infusion in acute heart failure. After early promise, the large RELAX-AHF-2 trial did not meet its primary endpoints, and the compound remains investigational and unapproved. Human data therefore exist but are ultimately negative for its lead indication.
BPC-157
Synthetic pentadecapeptide
A stable synthetic peptide based on a partial sequence identified in gastric juice. It is one of the most-studied research peptides for connective-tissue and gut-lining repair in animal models.
TB-500
Synthetic actin-binding peptide fragment
A synthetic fragment related to Thymosin Beta-4, a naturally occurring actin-regulating peptide. Studied in preclinical models for cell migration, wound healing, and flexibility.
SS-31
Mitochondria-targeting tetrapeptide
A mitochondria-targeting tetrapeptide, also known as elamipretide, studied clinically for mitochondrial diseases and other conditions involving mitochondrial dysfunction.